1. Home
  2. FSM vs IDYA Comparison

FSM vs IDYA Comparison

Compare FSM & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FSM

Fortuna Silver Mines Inc (Canada)

HOLD

Current Price

$10.27

Market Cap

3.1B

ML Signal

HOLD

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$32.31

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSM
IDYA
Founded
1990
2015
Country
Canada
United States
Employees
1633
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.9B
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
FSM
IDYA
Price
$10.27
$32.31
Analyst Decision
Buy
Strong Buy
Analyst Count
1
16
Target Price
$14.00
$51.21
AVG Volume (30 Days)
7.4M
765.5K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.90
EPS
N/A
N/A
Revenue
N/A
$218,710,000.00
Revenue This Year
$35.58
N/A
Revenue Next Year
N/A
$191.08
P/E Ratio
$14.10
N/A
Revenue Growth
N/A
3024.43
52 Week Low
$5.13
$13.45
52 Week High
$13.85
$39.28

Technical Indicators

Market Signals
Indicator
FSM
IDYA
Relative Strength Index (RSI) 49.46 50.54
Support Level $9.58 $29.29
Resistance Level $11.54 $34.86
Average True Range (ATR) 0.54 1.56
MACD 0.09 0.03
Stochastic Oscillator 82.82 55.66

Price Performance

Historical Comparison
FSM
IDYA

About FSM Fortuna Silver Mines Inc (Canada)

Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'voire, Mexico, and Peru. The company's segment consists of Mansfield, Sango, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d' Ivoire location.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: